This Phase III clinical trial compared the effectiveness of the combination of 1,3-bis(2-chloroethyl)-lnitrosourea (BCNU), radiation therapy, and hydroxyurea (BHR group) to the combination of BCNU and radiation therapy (BR group) for the treatment of malignant gliomas. In both arms of the study, BCNU was administered intravenously for 3 consecutive days before the initiation of radiation therapy, and at 8-week intervals thereafter until unequivocal tumor progression. In the BHR arm of the study, hydroxyurea was administered orally on alternate days during radiation therapy. Patients in each arm were stratified almost equally by tumor type (glioblastoma multiforme (GM) or other nonglioblastoma multiforme malignant gliomas (NGM)) and extent of surgical resection of tumor. Patients were also evaluated with the Karnofsky Performance Status (KPS) scale. Time to progression was determined by comparing the results of sequential neurological examinations and radionuclide and computerized tomographic scans.
H
YDROXYUREA (HU) is a cell cycle phase-specific drug reported to potentiate sublethal radiation damage in vitro? '1~ In combination with radiation therapy, HU is beneficial in the treatment of head and neck tumors 7,~~ and primary brain tumors. ', e This study was begun as Western Cancer Study Group Protocol 156. After the group disbanded, we continued the study independently at the Brain Tumor Research Center. The study was designed to evaluate the efficacy of HU given concomitantly with 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and radiation therapy to patients with both glioblastoma multiforme (GM) and other nonglioblastoma malignant gliomas (NGM).
Clinical Material

Patient Selection
All patients had malignant brain tumors diagnosed by angiogram, radionuclide brain scan, computerized tomographic (CT) brain scan, clinical neurological examination, and, in most cases, biopsy. Eligibility requirements were: 1) either histological diagnosis (GM, anaplastic astrocytoma, malignant glioma, mixed malignant glioma, or gemistocytic astrocytoma) or unequivocal clinical and neurodiagnostic evidence of a primary malignant brain tumor; 2) treatment initiated <4 weeks after surgery or clinical diagnosis; 3) life expectancy of >6 weeks; 4) normal results of complete blood count, platelet count, SMA-12 panel, urinalysis, GM  glioblastoma multiforme  35  25  60  gliosarcoma  1  1 t  2t  NGM  anaplastic astrocytoma  11  11  22  malignant glioma  5  7  12  gemistocytic astrocytoma  1  2  3  total  53  46  99 *BHR = BCNU, hydroxyurea, and radiation therapy; BR = BCNU and radiation therapy; GM = glioblastoma multiforme; NGM = nonglioblastoma malignant gliomas.
tBoth tumors had elements of glioblastoma intermingled with sarcomatous elements.
Stratification
Patients were stratified by histological type and by the extent of tumor resection. The two treatment groups consisted of 1) BCNU and radiation therapy (BR), and 2) BCNU and radiation therapy, with HU given during radiation therapy (BHR). Table 2 lists histological types for the two treatment  arms, and Table 3 summarizes tumor locations. In Table 4 , surgical procedures are listed for the two treatment groups.
Therapy
The BCNU was administered intravenously at a dosage of 80 mg/sq m on Days 1 to 3 in both treatment groups; on Day 4 radiation therapy was begun. One Day 5 HU was administered to the BHR group at a dosage of 275 mg/sq m every 6 hours, and repeated on alternate days until completion of radiation therapy. Patients were irradiated with either cobalt-60 or linear accelerator megavolt equipment. In the opposed lateral ports, the dosage to the whole brain was 5000 rads; a 1000-rad boost was given to the tumor area. Treatment functions were given at 170 to 200 rads/day. Two weeks after the completion of radiation therapy, BCNU was again given for 3 days and repeated every 8 weeks until tumor progression.
Myelotoxicity and gastrointestinal (GI) toxicity were carefully monitored. Reductions of BCNU doses were based on nadir counts of white blood cells and platelets between courses. Patients were given higher doses if they could tolerate them, and patients who showed no bone marrow toxicity received subsequent doses of BCNU higher than 80 mg/sq m. In no patient did BCNU cause significant GI toxicity, but HU was less well tolerated. Of 55 patients receiving HU, 15 tolerated the drug with no ill effects, eight had their doses temporarily reduced, and three had the drug total resection 1 0 1 1 *BHR = BCNU, hydroxyurea, and radiation therapy; BR = BCNU and radiation therapy; GM = glioblastoma multiforme; NGM = nonglioblastoma malignant gliomas.
tTen GM patients were diagnosed by biopsy and two at autopsy. Three diagnoses in NGM patients with BHR were confirmed by biopsy; of the remaining three patients diagnosed by neuroradiological and clinical criteria, no autopsies were performed. No NGM patients with BR were confirmed by biopsy; one still alive, two confirmed by autopsy, and one died with autopsy-proven radiation necrosis and no tumor; no autopsies were performed on two patients. temporarily stopped; 19 patients had their doses permanently reduced, and 10 had the drug permanently stopped.
Glucocorticoid dosage was adjusted as indicated to improve the level of neurological function and to reduce headache and nausea. Because improvement caused by steroids can mimic response to cytotoxic therapy, doses were increased only when required to offset marked clinical deterioration. Attempts were made to reduce the steroid dosage every 8 weeks if patients were stable or improving. Anticonvulsants and anti-emetics were used as medically indicated.
Results
Of the 99 patients in the valid study group, 88 were diagnosed histologically prior to randomization. Eleven patients harboring malignant gliomas diagnosed on the basis of clinical and neuroradiological criteria were randomized into the study; one patient remains in remission, diagnosis of five patients was confirmed at autopsy, and five patients were unverified and classified as NGM.
Response to therapy was determined from results of a neurological examination and RN and CT scans) These tests were performed every 8 weeks at the time of BCNU administration, and were compared to the results of the preceding tests. Patients were followed until tumor progression, at which time therapy was discontinued, changed, or continued only for humanitarian reasons. "Response" was defined as improvement in at least two of the three tests in the same or consecutive evaluations, provided that the patient had not had his/her steroid dose increased since the last course of therapy. "Stable disease" was defined as no change in the three tests or improvement in only one, or deterioration in only one test. "Tumor progression" was defined as deterioration in two of three tests in the same or consecutive evaluations, provided that steroids had not been decreased. The overall activity level of patients was evaluated by the Karnofsky Performance Status (KPS) scale at the time of randomization and before each treatment. Figure 1 left is a Kaplan-Meier representation 5 of time to tumor progression for all GM patients. The difference between the BHR and BR treatment groups was found to be significant at p = 0.04 by the Gehanmodified Wilcoxon rank sum analysis. 2 According to the dose of HU actually taken by each patient, the difference between the two groups was significant at p < 0.05 by the Cox analysis? Figure 1 right is a Kaplan-Meier representation of time to tumor progression for the NGM patients; 17 patients received HU and 20 did not. This curve shows little difference in time to progression between the two treatment groups. The NGM patients have a longer time to progression than GM patients. However, the relationship between response and dose of HU is not statistically significant. In order to determine time to tumor progression for "better risk" patients, we divided patients by tumor type and KPS at the beginning of therapy. Patients with GM and KPS > 60 are represented in Fig. 2 left. The difference between the BHR and BR treatment groups is significant by both Gehan (p = 0.04) and Cox (p = 0.026) analyses. The NGM patients with KPS > 60, represented in Fig. 2 right, did not benefit from HU. 120 BR arms is statistically significant (p = 0.03 by Gehan analysis and p = 0.026 by Cox analysis) for the GM patients, but nonsignificant for the NGM patients. Too few NGM patients (eight BHR and 13 BR patients) were available to make a similar analysis. Table 5 is a summary of the median time to tumor progression (MTP) for Figs. 1 to 3. Patients who benefit from HU harbor the most malignant of astrocytic tumors, glioblastoma multiforme. Response to therapy (Table 6 ) is similar for the GM and NGM patients in both treatment arms. Figure 4 shows the age distribution of patients by tumor type in both treatment groups. The BHR arm had a greater number of elderly patients, who generally tolerate less drug and have a shorter survival time than younger patients. Thus, we actually anticipated that BHR patients in the GM and NGM groups would have a shorter time to progression than patients in comparable BR groups; this was not observed for the GM patients, but might have been a factor in the NGM patients. Table 7 *BHR = BCNU, hydroxyurea, and radiation therapy; BR = BCNU and radiation therapy. GM = glioblastoma multiforme; NGM = nonglioblastoma malignant gliomas; NS = not significant.
tGehan modification of the Wilcoxon rank sum analysis. :~Cox analysis based on actual hydroxyurea dose. *BHR = BCNU, hydroxyurea, and radiation therapy; BR = BCNU and radiation therapy; GM = glioblastoma multiforme; NGM = nonglioblastoma malignant gliomas.
patients. Figure 5 shows the average BCNU dose (in mg/sq m/week) for all the first five courses of therapy. A patient who received the full dose of 80 mg/sq m for 3 days every 8 weeks would average 30 mg/sq m/week.
Patient tolerance of HU is discussed above. Only two patients received less than 12% of the prescribed dose. One patient had antral gastritis before receiving HU and could not tolerate the drug for more than a few days; the other refused to continue the drug because of severe GI distress. For statistical analysis, these two patients were evaluated in the BR treatment group. Figure 6 shows the frequency distribution of HU dose/week. The full prescribed dose would be 3.85 gm/sq m/week. 
Discussion
The goal of this study was to determine if concomitant BCNU, HU, and radiation therapy would be a more effective treatment for malignant brain tumors than BCNU and irradiation. Time to tumor progression, as evaluated by neurological examination and radionuclide and CT scans, was the primary end point of this study. Patients harboring GM were stratified separately from patients harboring anaplastic astrocytoma, malignant glioma, gemistocytic astrocytoma, and mixed malignant glioma (NGM patients).
Most significantly, GM patients who received HU had a longer time to tumor progression than GM patients who did not receive HU. The GM patients who did not receive HU had an MTP of 31 weeks regardless of stratification by Karnofsky Performance Status or the extent of surgical resection, which correlates well with the median survival time of 37 weeks reported by the Brain Tumor Study Group? 3 The GM patients who had subtotal or total resection of tumor and who received HU had an MTP of 49 weeks. This 4-month increase in time to progression is statistically significant and is dependent on the dose of HU administered.
Disappointingly, NGM patients did not benefit from HU, with MTP's of 72 to 73 weeks without HU and 50 to 56 weeks with HU (depending on KPS and extent of resection of tumor). While the BR arm appears superior to the BHR arm, the two groups did not differ statistically, and the Kaplan-Meier plots (Figs. 1 right and 2 right) were parallel. This lack of difference between the BR and BHR groups may reflect the greater age of the NGM patient population, heterogeneity of tumor types in the NGM group, and the small number of patients in each histological classification, which precludes statistical analysis by tumor type in this group.
The lack of effect of HU in NGM tumors confirms fundamental biological differences between GM and NGM tumors. We hypothesize that NGM tumors are more homogeneous than GM tumors in both oxygenation and proliferative capacity. The fact that HU, a cell cycle phase-specific drug, together with BCNU, a cell cycle nonspecific drug, have greater activity against GM tumors suggests that their ability to synchronize cells to enhance radiation-induced cell kill may be greater for GM tumors than for NGM tumors. While the growth fraction of most malignant intracranial gliomas is quite low, 8 the labeling index for GM tumors is higher than for the NGM tumors, and GM tumors may recruit cells into the cycling pool more readily than NGM tumors.
This study shows that HU is an effective adjunct to BCNU and radiation therapy for patients harboring glioblastoma multiforme, but not for patients harboring other malignant glial tumors. Future therapy for patients harboring glioblastoma multiforme can be developed to take further advantage of BCNU and HU chemotherapy administered during radiation therapy.
